EC2629 (folate receptor-targeted pro-PBD)
Delivers a potent DNA-reactive cytotoxic agent to folate receptor-positive cancer cells and TAMs
EC2629 is an investigational, proprietary folate receptor-targeted SMDC which utilizes a potent DNA-reactive cytotoxic agent to treat cancer. Strong anti-tumor effect has been observed preclinically in xenograft models safely treated with EC2629, including curative activity against triple negative breast cancer and drug-resistant ovarian cancer. EC2629 is unique in that it targets and eliminates both folate receptor positive cancer cells as well as the tumor-associated macrophages (TAMs) that reside within the tumor environment. Preclinical development of EC2629 is currently underway with a projected IND filing in 2017.
* The safety and efficacy of these agents have not been established. There is no guarantee that the agents will receive regulatory approval and become commercially available for the uses being investigated.